Eisai Clinical Trials

A 54-week, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcomes in Patients with Alzheimer’s Disease.


Study Overview

Not available
Jul 1996 - Oct 1998
Alzheimer's disease
The primary efficacy endpoint was to evaluate the efficacy (primary efficacy assessed on the basis of attrition from the study due to clinically evident functional decline) of donepezil HCI E2020, versus Placebo, in the management of Alzheimer's disease.

  • Males and females (age 50 years and over)

  • Completed

  • Phase 3

  • United States


CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481-8.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Sample CRF
Full CSR